- The World Chemical Outlook is worthwhile. I liked this quote from Cambrex's CEO in Rick Mullin's that smaller drug startups like to be "touchy-feely" when dealing with fine chemicals manufacturers -- can't say I blame them, really.
- I was rather bemused at this comment in Lisa Jarvis' article on the pharma outlook from an Ernst and Young analyst: "Flochel expects the headcount reductions to continue in 2014 but says they will be weighted toward sales, manufacturing, and supply-chain positions, rather than the deep cuts to R&D seen in recent years. “There’s a limit to how much you can cut because then you cut in the muscle rather than the fat,” he says." Oh, we're only getting to the muscle now?!? I'm pretty sure we hit the bone in 2009, maybe 2011.
- The U.S. had a lower proportion of the world's biomedical R&D spending in 2012, attributable mainly to lower industrial spending. (article by Rick Mullin)
- Chuck Schumer wants to phase out an older model of tank car, potentially responsible for recent incidents where after the tank cars full of Bakken crude derail, they explode. Oh, dear. (article by Glenn Hess.)
- Can anyone make heads or tails of this letter to the editor about Canadian science? It's confusing as all get-out.
Monday, January 13, 2014
This week's C&EN
Lots of interesting stuff in this week's C&EN: